RCM
SAGE

Riverhead Capital Management’s Sage Therapeutics SAGE Stock Holding History

Riverhead Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$22K Hold
156
– – ﹤0.01% 1468
2019
Q2 		$29K Buy
156
+5
+3% +$853 ﹤0.01% 1482
2019
Q1 		$24K Buy
151
+44
+41% +$6.37K ﹤0.01% 1467
2018
Q4 		$10K Sell
107
-150
-58% -$17.2K ﹤0.01% 1481
2018
Q3 		$36K Buy
+257
New +$39.7K ﹤0.01% 1514
2018
Q2 		– Sell
-38
Closed -$6K – 1566
2018
Q1 		$6K Buy
+38
New +$6.45K ﹤0.01% 1532

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Riverhead Capital Management's SAGE Position: Q3 2019 in Review

Riverhead Capital Management held its Sage Therapeutics (SAGE) position steady in Q3 2019 at 156 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

Riverhead Capital Management first reported a position in SAGE in Q1 2018 and has held it in 6 quarters since. The position peaked at $36K in Q3 2018. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Riverhead Capital Management held 156 shares of Sage Therapeutics worth $22K as of Q3 2019.
  • Riverhead Capital Management left its Sage Therapeutics share count unchanged in Q3 2019.
  • Sage Therapeutics made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1468 holding.
  • Riverhead Capital Management first reported a position in Sage Therapeutics in Q1 2018 and has held it in 6 quarters since.
  • Riverhead Capital Management's Sage Therapeutics position peaked at $36K in Q3 2018.
  • 285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.